Tamoxifen through GPER upregulates aromatase expression: A novel mechanism sustaining tamoxifen-resistant breast cancer cell growth

Breast Cancer Research and Treatment

Volumn 146, Issue 2, 2014, Pages 273-285

  Catalano, Stefania ^a   Giordano, Cinzia ^a   Panza, Salvatore ^a   Chemi, Francesca ^a   Bonofiglio, Daniela ^a   Lanzino, Marilena ^a   Rizza, Pietro ^a   Romeo, Francesco ^b   Fuqua, Suzanne A W ^c   Maggiolini, Marcello ^a   Andò, Sebastiano ^a   Barone, Ines ^a  

^a UNIVERSITY OF CALABRIA   (Italy)

^b Annunziata Hospital   (Italy)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Aromatase; Breast cancer; GPER; Tamoxifen resistance

Indexed keywords

AROMATASE; ESTROGEN; G PROTEIN COUPLED RECEPTOR 30; PROTEIN C FOS; PROTEIN C JUN; TAMOXIFEN; TRANSCRIPTION FACTOR AP 1; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; ESTROGEN RECEPTOR; G PROTEIN COUPLED RECEPTOR; GPER PROTEIN, HUMAN; PROTEIN BINDING;

AROMATASE GENE; ARTICLE; BREAST CANCER; CANCER CELL; CANCER RESISTANCE; CELL GROWTH; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; ENZYME ACTIVITY; GEL MOBILITY SHIFT ASSAY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MCF 7 CELL LINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; BREAST TUMOR; DRUG EFFECTS; DRUG RESISTANCE; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; PROMOTER REGION; TRANSCRIPTION INITIATION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE; BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MCF-7 CELLS; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-FOS; PROTO-ONCOGENE PROTEINS C-JUN; RECEPTORS, ESTROGEN; RECEPTORS, G-PROTEIN-COUPLED; TAMOXIFEN; TRANSCRIPTION FACTOR AP-1; TRANSCRIPTIONAL ACTIVATION;

EID: 84904097424     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-014-3017-4     Document Type: Article

References (66)

1. Harada N (1997) Aberrant expression of aromatase in breast cancer tissues. J Steroid Biochem Mol Biol 61:175-184
2. James VH, McNeill JM, Lai LC et al (1987) Aromatase activity in normal breast and breast tumor tissues: in vivo and in vitro studies. Steroids 50:269-279
3. Esteban JM, Warsi Z, Haniu M et al (1992) Detection of intratumoral aromatase in breast carcinomas. An immunohistochemical study with clinicopathologic correlation. Am J Pathol 140:337-343
4. Chen S, Masri S, Wang X et al (2006) What do we know about the mechanisms of aromatase inhibitor resistance? J Steroid Biochem Mol Biol 102:232-240 (Pubitemid 44750638)
5. Simpson ER, Michael MD, Agarwal VR et al (1997) Cytochromes P450 11: expression of the CYP19 (aromatase) gene: an unusual case of alternative promoter usage. FASEB J 11:29-36 (Pubitemid 27076321)
6. Bulun SE, Sebastian S, Takayama K et al (2003) The human CYP19 (aromatase P450) gene: update on physiologic roles and genomic organization of promoters. J Steroid Biochem Mol Biol 86:219-224 (Pubitemid 37412560)
7. Barone I, Giordano C, Malivindi R et al (2012) Estrogens and PTP1B function in a novel pathway to regulate aromatase enzymatic activity in breast cancer cells. Endocrinology 153:5157-5166
8. Catalano S, Barone I, Giordano C et al (2009) Rapid estradiol/ERalpha signaling enhances aromatase enzymatic activity in breast cancer cells. Mol Endocrinol 23:1634-1645
9. Maggiolini M, Carpino A, Bonofiglio D et al (2001) The direct proliferative stimulus of dehydroepiandrosterone on MCF7 breast cancer cells is potentiated by overexpression of aromatase. Mol Cell Endocrinol 184:163-171 (Pubitemid 32994806)
10. Sun XZ, Zhou D, Chen S (1997) Autocrine and paracrine actions of breast tumor aromatase. A three-dimensional cell culture study involving aromatase transfected MCF-7 and T-47D cells. J Steroid Biochem Mol Biol 63:29-36 (Pubitemid 28018134)
11. Yue W, Zhou D, Chen S et al (1994) A new nude mouse model for postmenopausal breast cancer using MCF-7 cells transfected with the human aromatase gene. Cancer Res 54:5092-5095 (Pubitemid 24313482)
12. Tekmal RR, Ramachandra N, Gubba S et al (1996) Overexpression of int-5/aromatase in mammary glands of transgenic mice results in the induction of hyperplasia and nuclear abnormalities. Cancer Res 56:3180-3185 (Pubitemid 26242957)
13. Prossnitz ER, Maggiolini M (2009) Mechanisms of estrogen signaling and gene expression via GPR30. Mol Cell Endocrinol 308:32-38
14. Revankar CM, Cimino DF, Sklar LA et al (2005) A transmembrane intracellular estrogen receptor mediates rapid cell signaling. Science 307:1625-1630 (Pubitemid 40354745)
15. Filardo EJ (2002) Epidermal growth factor receptor (EGFR) transactivation by estrogen via the G-protein-coupled receptor, GPR30: a novel signaling pathway with potential significance for breast cancer. J Steroid Biochem Mol Biol 80:231-238
16. Prossnitz ER, Oprea TI, Sklar LA et al (2008) The ins and outs of GPR30: a transmembrane estrogen receptor. J Steroid Biochem Mol Biol 109:350-353
17. Filardo EJ, Quinn JA, Bland KI et al (2000) Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF. Mol Endocrinol 14:1649-1660
18. Pandey DP, Lappano R, Albanito L et al (2009) Estrogenic GPR30 signalling induces proliferation and migration of breast cancer cells through CTGF. EMBO J 28:523-532
19. Thomas P, Pang Y, Filardo EJ et al (2005) Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells. Endocrinology 146:624-632 (Pubitemid 40129818)
20. Vivacqua A, Bonofiglio D, Recchia AG et al (2006) The G protein-coupled receptor GPR30 mediates the proliferative effects induced by 17beta-estradiol and hydroxytamoxifen in endometrial cancer cells. Mol Endocrinol 20:631-646 (Pubitemid 43291214)
21. Vivacqua A, Bonofiglio D, Albanito L et al (2006) 17beta-estradiol, genistein, and 4-hydroxytamoxifen induce the proliferation of thyroid cancer cells through the g protein-coupled receptor GPR30. Mol Pharmacol 70:1414-1423 (Pubitemid 44435994)
22. Encarnacion CA, Ciocca DR, McGuire WL et al (1993) Measurement of steroid hormone receptors in breast cancer patients on tamoxifen. Breast Cancer Res Treat 26:237-246 (Pubitemid 23304239)
23. Giordano C, Cui Y, Barone I et al (2009) Growth factor-induced resistance to tamoxifen is associated with a mutation of estrogen receptor alpha and its phosphorylation at serine 305. Breast Cancer Res Treat 119:71-85
24. Barone I, Brusco L, Fuqua SA (2010) Estrogen receptor mutations and changes in downstream gene expression and signaling. Clin Cancer Res 16:2702-2708
25. Barone I, Iacopetta D, Covington KR et al (2010) Phosphorylation of the mutant K303R estrogen receptor alpha at serine 305 affects aromatase inhibitor sensitivity. Oncogene 29:2404-2414
26. Barone I, Cui Y, Herynk MH et al (2009) Expression of the K303R estrogen receptor-alpha breast cancer mutation induces resistance to an aromatase inhibitor via addiction to the PI3K/Akt kinase pathway. Cancer Res 69:4724-4732
27. Blume-Jensen P, Hunter T (2001) Oncogenic kinase signalling. Nature 411:355-365 (Pubitemid 32467045)
28. Martin LA, Farmer I, Johnston SR et al (2003) Enhanced estrogen receptor (ER) alpha, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation. J Biol Chem 278:30458-30468 (Pubitemid 36994549)
29. Schiff R, Massarweh SA, Shou J et al (2004) Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. Clin Cancer Res 10:331S-336S (Pubitemid 38116639)
30. Sabnis GJ, Jelovac D, Long B et al (2005) The role of growth factor receptor pathways in human breast cancer cells adapted to long-term estrogen deprivation. Cancer Res 65:3903-3910 (Pubitemid 40616372)
31. Staka CM, Nicholson RI, Gee JM (2005) Acquired resistance to oestrogen deprivation: role for growth factor signalling kinases/oestrogen receptor cross-talk revealed in new MCF-7X model. Endocr Relat Cancer 12(Suppl 1):S85-S97 (Pubitemid 41395416)
32. Evan GI, Brown L, Whyte M et al (1995) Apoptosis and the cell cycle. Curr Opin Cell Biol 7:825-834
33. Ignatov A, Ignatov T, Roessner A et al (2010) Role of GPR30 in the mechanisms of tamoxifen resistance in breast cancer MCF-7 cells. Breast Cancer Res Treat 123:87-96
34. Ignatov A, Ignatov T, Weissenborn C et al (2011) G-protein-coupled estrogen receptor GPR30 and tamoxifen resistance in breast cancer. Breast Cancer Res Treat 128:457-466
35. Vivacqua A, Lappano R, De Marco P et al (2009) G protein-coupled receptor 30 expression is up-regulated by EGF and TGF alpha in estrogen receptor alpha-positive cancer cells. Mol Endocrinol 23:1815-1826
36. Lin BC, Suzawa M, Blind RD et al (2009) Stimulating the GPR30 estrogen receptor with a novel tamoxifen analogue activates SF-1 and promotes endometrial cell proliferation. Cancer Res 69:5415-5423
37. Barone I, Brusco L, Gu G et al (2011) Loss of Rho GDIalpha and resistance to tamoxifen via effects on estrogen receptor alpha. J Natl Cancer Inst 103:538-552
38. Barone I, Catalano S, Gelsomino L et al (2012) Leptin mediates tumor-stromal interactions that promote the invasive growth of breast cancer cells. Cancer Res 72:1416-1427
39. Catalano S, Marsico S, Giordano C et al (2003) Leptin enhances, via AP-1, expression of aromatase in the MCF-7 cell line. J Biol Chem 278:28668-28676 (Pubitemid 36935773)
40. Albanito L, Sisci D, Aquila S et al (2008) Epidermal growth factor induces G protein-coupled receptor 30 expression in estrogen receptor-negative breast cancer cells. Endocrinology 149:3799-3808
41. Catalano S, Malivindi R, Giordano C et al (2010) Farnesoid X receptor, through the binding with steroidogenic factor 1-responsive element, inhibits aromatase expression in tumor Leydig cells. J Biol Chem 285:5581-5593
42. Plastina P, Bonofiglio D, Vizza D et al (2012) Identification of bioactive constituents of Ziziphus jujube fruit extracts exerting antiproliferative and apoptotic effects in human breast cancer cells. J Ethnopharmacol 140:325-332
43. Catalano S, Panza S, Malivindi R et al (2013) Inhibition of Leydig tumor growth by farnesoid X receptor activation: the in vitro and in vivo basis for a novel therapeutic strategy. Int J Cancer 132:2237-2247
44. Andrews NC, Faller DV (1991) A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells. Nucleic Acids Res 19:2499
45. Gu G, Barone I, Gelsomino L et al (2012) Oldenlandia diffusa extracts exert antiproliferative and apoptotic effects on human breast cancer cells through ERalpha/Sp1-mediated p53 activation. J Cell Physiol 227:3363-3372
46. Giordano C, Catalano S, Panza S et al (2011) Farnesoid X receptor inhibits tamoxifen-resistant MCF-7 breast cancer cell growth through downregulation of HER2 expression. Oncogene 30:4129-4140
47. Macedo LF, Guo Z, Tilghman SL et al (2006) Role of androgens on MCF-7 breast cancer cell growth and on the inhibitory effect of letrozole. Cancer Res 66:7775-7782 (Pubitemid 44289238)
48. Lanzino M, Maris P, Sirianni R et al (2013) DAX-1, as an androgen-target gene, inhibits aromatase expression: a novel mechanism blocking estrogen-dependent breast cancer cell proliferation. Cell Death Dis 4:e724
49. Maggiolini M, Vivacqua A, Fasanella G et al (2004) The G protein-coupled receptor GPR30 mediates c-fos up-regulation by 17beta-estradiol and phytoestrogens in breast cancer cells. J Biol Chem 279:27008-27016 (Pubitemid 38812536)
50. Carmeci C, Thompson DA, Ring HZ et al (1997) Identification of a gene (GPR30) with homology to the G-protein-coupled receptor superfamily associated with estrogen receptor expression in breast cancer. Genomics 45:607-617 (Pubitemid 27506136)
51. Vivacqua A, Romeo E, De Marco P et al (2012) GPER mediates the Egr-1 expression induced by 17beta-estradiol and 4-hydroxitamoxifen in breast and endometrial cancer cells. Breast Cancer Res Treat 133:1025-1035
52. Albanito L, Madeo A, Lappano R et al (2007) G protein-coupled receptor 30 (GPR30) mediates gene expression changes and growth response to 17beta-estradiol and selective GPR30 ligand G-1 in ovarian cancer cells. Cancer Res 67:1859-1866 (Pubitemid 46383413)
53. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57-70 (Pubitemid 30046295)
54. Albanito L, Lappano R, Madeo A et al (2008) G-protein-coupled receptor 30 and estrogen receptor-alpha are involved in the proliferative effects induced by atrazine in ovarian cancer cells. Environ Health Perspect 116:1648-1655
55. Filardo EJ, Graeber CT, Quinn JA et al (2006) Distribution of GPR30, a seven membrane-spanning estrogen receptor, in primary breast cancer and its association with clinicopathologic determinants of tumor progression. Clin Cancer Res 12:6359-6366 (Pubitemid 44799705)
56. Sirianni R, Chimento A, Ruggiero C et al (2008) The novel estrogen receptor, G protein-coupled receptor 30, mediates the proliferative effects induced by 17beta-estradiol on mouse spermatogonial GC-1 cell line. Endocrinology 149:5043-5051
57. Kuo WH, Chang LY, Liu DL et al (2007) The interactions between GPR30 and the major biomarkers in infiltrating ductal carcinoma of the breast in an Asian population. Taiwan J Obstet Gynecol 46:135-145 (Pubitemid 47236783)
58. Angel P, Karin M (1991) The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. Biochim Biophys Acta 1072:129-157 (Pubitemid 121007534)
59. Morgan L, Gee J, Pumford S et al (2009) Elevated Src kinase activity attenuates tamoxifen response in vitro and is associated with poor prognosis clinically. Cancer Biol Ther 8:1550-1558
60. Fan P, Wang J, Santen RJ et al (2007) Long-term treatment with tamoxifen facilitates translocation of estrogen receptor alpha out of the nucleus and enhances its interaction with EGFR in MCF-7 breast cancer cells. Cancer Res 67:1352-1360
61. Fidler IJ (2003) The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer 3:453-458
62. Witz IP (2008) Yin-Yang activities and vicious cycles in the tumor microenvironment. Cancer Res 68:9-13
63. Martinez-Outschoorn UE, Goldberg A, Lin Z et al (2011) Antiestrogen resistance in breast cancer is induced by the tumor microenvironment and can be overcome by inhibiting mitochondrial function in epithelial cancer cells. Cancer Biol Ther 12:924-938
64. Madeo A, Maggiolini M (2010) Nuclear alternate estrogen receptor GPR30 mediates 17beta-estradiol-induced gene expression and migration in breast cancer-associated fibroblasts. Cancer Res 70:6036-6046
65. Normanno N, Di Maio M, De Maio E et al (2005) Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer. Endocr Relat Cancer 12:721-747 (Pubitemid 41815773)
66. Mo Z, Liu M, Yang F et al (2013) GPR30 as an initiator of tamoxifen resistance in hormone-dependent breast cancer. Breast Cancer Res 15:R114